Synairgen plc
('Synairgen' or the 'Company')
Martin Murphy appointed as Non-Executive Director
Southampton, UK - 16 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately.
Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
Mark Parry-Billings, Chairman of the Board of Synairgen, added: "I'm pleased to welcome Martin Murphy to our Board at Synairgen, where his proven track record in guiding innovative healthcare companies will strengthen our strategic direction. Martin's extensive experience in life sciences leadership will prove invaluable as we prepare to begin our large Phase 2 INVENT trial in the coming months."
Martin Murphy, Non-Executive Director of the Board of Synairgen, commented: "I am delighted to be joining Synairgen's Board at this pivotal stage as the Company plans to progress its INVENT trial investigating SNG001 in mechanically ventilated patients. I look forward to collaborating with the team and supporting the advancement of this potentially transformative treatment for a patient group in critical need."
The following information regarding the appointment of Martin Murphy, aged 56, is disclosed under Schedule 2(g) of the AIM Rules for Companies:
| Full name: | Martin Patrick Murphy |
| Age: | 56 |
| Shares held in the Company: | None |
| Current directorships and/or partnerships: | Former directorships and/or partnerships (within the last five years): |
| Autolus Therapeutics PLC (formerly Autolus Therapeutics Limited) | Achilles Therapeutics UK Limited |
| | Anaveon AG |
| | Azeria Therapeutics Limited |
| | Clade Therapeutics, Inc. |
| | Neogene Therapeutics, Inc. |
| | Quell Therapeutics Limited |
| | Resolution Therapeutics Limited |
| | Syncona Development Limited |
| | Syncona Discovery Limited |
| | Syncona Investment Management Limited |
| | Syncona IP Holdco (2) Limited |
| | Syncona IP Holdco Limited |
There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.
For further enquiries, please contact:
| Synairgen plc | + 44 (0)23 8051 2800 |
| | |
| Cavendish Capital Markets Limited - | + 44 (0)20 7220 0500 |
| Geoff Nash/Camilla Hume/Trisyia Jamaludin Deutsche Numis (Joint Broker) Freddie Barnfield, Duncan Monteith, Euan Brown
|
+ 44 (0) 20 7260 1000 |
| ICR Healthcare (Financial Media and Investor Relations) | + 44 (0)20 3709 5700 |
| Mary-Jane Elliott/Namrata Taak/Lucy Featherstone | |
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
